{"gene":"FLI1","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":1993,"finding":"FLI1 protein binds specific DNA sequences related to ETS-binding sites and functions as a transcriptional activator, with two autonomous transcriptional activation domains (N-terminal and C-terminal regions).","method":"DNA binding assays, methylation protection experiments, co-transfection reporter assays, deletion analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple in vitro and functional assays with deletion analysis establishing DNA binding and transactivation","pmids":["8449942"],"is_preprint":false},{"year":1993,"finding":"EWS/FLI1 chimeric fusion protein functions as a transcriptional activator; the EWS domain acts as a modulatory/regulatory domain for the C-terminal transcriptional activation domain of FLI1, with the EWS-FLI1 fusion releasing the C-terminal activation domain from inhibition imposed by the normal FLI1 N-terminal region.","method":"Reporter gene assays, deletion analysis, transient transfection","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 — direct functional dissection with deletion mutagenesis and reporter assays","pmids":["7503813"],"is_preprint":false},{"year":1995,"finding":"EWS/FLI1 transformation of NIH3T3 cells requires both EWS and FLI1 sequences; the EWS domain encodes a strong transcriptional activation domain and can be functionally subdivided into a transformation-efficient but low-transactivation domain (A) and a high-transactivation but less-transformation-efficient domain (B); EWS/FLI1 cooperates with other transcription factors to activate reporter genes.","method":"Soft agar colony assays, reporter gene transactivation assays, deletion mutant analysis, chimeric construct transfection","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 — systematic deletion and domain-swap mutagenesis with functional transformation readout","pmids":["7845667"],"is_preprint":false},{"year":1996,"finding":"EWS-FLI1, but not FLI1, forms a ternary complex on the c-fos serum response element (SRE) by interacting with SRF protein; both FLI1 and EWS-FLI1 interact with SRF in vitro in the absence of DNA; deletion of the N-terminal domain of FLI1 converts it to EWS-FLI1-like behavior, revealing an N-terminal inhibitory domain in normal FLI1.","method":"EMSA, GST pull-down, deletion mutagenesis","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with mutagenesis and pull-down confirming SRF interaction","pmids":["8604338"],"is_preprint":false},{"year":1997,"finding":"EWS/FLI1 transformation requires the presence of a functional IGF-IR; IGF-IR knockout fibroblasts expressing EWS/FLI1 fail to form soft agar colonies; EWS/FLI1 expression enhances ligand-stimulated IRS-1 phosphorylation, indicating alteration of IGF-IR signaling.","method":"Soft agar colony assay using IGF-IR knockout vs. wild-type fibroblasts, IRS-1 phosphorylation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis using knockout cells with defined transformation and signaling readouts","pmids":["9388225"],"is_preprint":false},{"year":1998,"finding":"TEL (ETV6) binds directly to FLI1 via its helix-loop-helix domain and inhibits FLI1-mediated transactivation of megakaryocytic promoters; full inhibition requires the complete TEL molecule including its DNA-binding domain.","method":"Yeast two-hybrid screen, in vitro and in vivo binding assays, transient transfection with deletion mutants","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal binding confirmed in vitro and in vivo with functional transactivation assays and deletion analysis","pmids":["9651344"],"is_preprint":false},{"year":1999,"finding":"FLI1 overexpression in primary erythroblasts inhibits apoptosis (correlating with bcl2 upregulation), inhibits terminal differentiation, and induces proliferation; it prevents downregulation of cyclins D2 and D3 during differentiation.","method":"Retroviral transduction of primary avian erythroblasts, Epo deprivation/differentiation assays, Western blot for BCL2/cyclins","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — primary cell loss/gain-of-function with multiple molecular readouts","pmids":["10102630"],"is_preprint":false},{"year":2001,"finding":"FLI1 inhibits COL1A2 (collagen alpha2(I)) promoter activity in dermal fibroblasts via direct DNA binding to a critical ETS site and via indirect protein-protein interaction through Sp1; FLI1 competes with ETS-1 at the COL1A2 promoter; an Sp1-FLI1 complex may recruit a co-repressor for maximal inhibition.","method":"Stable transfection, reporter/promoter assays, in vitro DNA-protein binding assays, dominant-negative and DNA-binding mutants, Gal4 fusion experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro binding, mutagenesis, and multiple reporter assays with dominant-negative constructs","pmids":["11278621"],"is_preprint":false},{"year":2003,"finding":"FLI1 represses EKLF-dependent beta-globin transcription by using the repression activity of its ETS DNA-binding domain and indirect recruitment to erythroid promoters via protein-protein interaction with EKLF; FLI1 enhances GATA-1 activity but represses EKLF activity; EKLF reciprocally represses FLI1-dependent megakaryocytic GPIX promoter, establishing a cross-antagonism controlling erythroid vs. megakaryocytic fate.","method":"Transient transfection reporter assays, co-immunoprecipitation, Gal4 fusion assays, deletion mutant analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal functional assays with multiple promoters, protein interaction studies, and domain-mapping","pmids":["12556498"],"is_preprint":false},{"year":2003,"finding":"EWS/FLI1 blocks myogenic differentiation in C2C12 myoblasts requiring nuclear localization and DNA-binding functions; it suppresses MyoD and myogenin at transcriptional and post-transcriptional levels, and constitutively induces cyclin D1 while decreasing p21(cip1).","method":"Retroviral transduction of C2C12 cells, differentiation assays, RT-PCR, Western blot, DNA-binding mutant analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — clean loss/gain-of-function with DNA-binding domain mutants and defined molecular readouts","pmids":["12509448"],"is_preprint":false},{"year":2005,"finding":"FLI1 directly binds the MDM2 promoter at a consensus ETS binding site in vitro and in vivo, activating MDM2 transcription; FLI1 overexpression correlates with elevated MDM2 and reduced p53 in erythroleukemic tissues.","method":"Chromatin immunoprecipitation, in vitro DNA binding assay, reporter gene assay, in vivo tissue correlation","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — ChIP confirming in vivo binding plus reporter assay with in vivo correlation","pmids":["15592502"],"is_preprint":false},{"year":2005,"finding":"FLI1, ELF1, and ETS1 bind conserved Ets sites in the LMO2 proximal promoter in vivo in hematopoietic progenitor and endothelial cells, controlling LMO2 transcription; transgenic analysis confirmed this promoter is sufficient for endothelial expression in vivo.","method":"ChIP, transient and stable transfection, real-time RT-PCR, transgenic mouse analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — in vivo ChIP combined with transgenic validation","pmids":["15994290"],"is_preprint":false},{"year":2006,"finding":"RNA helicase A (RHA) physically binds EWS-FLI1 (residues 630-1020 of RHA); endogenous RHA forms a complex with EWS-FLI1 in ESFT cells; both proteins co-occupy EWS-FLI1 target gene promoters; RHA stimulates EWS-FLI1 transcriptional activity including Id2, and enhances anchorage-independent growth when co-expressed with EWS-FLI1.","method":"Phage display screening, GST pull-down, ELISA, co-immunoprecipitation, ChIP, transcriptional reporter assays, soft agar colony assay","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal binding methods (phage display, GST pulldown, co-IP, ChIP) with functional transcriptional and transformation readouts","pmids":["16740692"],"is_preprint":false},{"year":2007,"finding":"GATA2, FLI1, and SCL/TAL1 form a recursively wired gene-regulatory circuit during hematopoietic specification; each transcription factor binds to the enhancers of the other two (Fli1+12, Gata2-3, Scl+19 enhancers), all of which use Ets/GATA/E-Box motif clusters; these enhancers are co-occupied by all three factors in HSCs, fetal liver, and hemangioblast equivalents.","method":"ChIP, enhancer-driven reporter assays, transgenic analysis, conservation analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — genome-wide ChIP with functional enhancer validation across multiple cell types","pmids":["17962413"],"is_preprint":false},{"year":2014,"finding":"FLI1 directly binds Ets-binding sites within the CCL5 promoter and drives its transcription in a dose-dependent manner; mutation of FLI1 DNA-binding domain reduces CCL5 promoter transactivation; ETS1 acts as a dominant-negative for FLI1 at shared CCL5 promoter sites.","method":"ChIP, siRNA knockdown, transient transfection reporter assays, site-directed mutagenesis","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — ChIP confirming in vivo binding combined with promoter mutation and reporter assays","pmids":["25098295"],"is_preprint":false},{"year":2014,"finding":"FLI1 acts downstream of ETV2 in vascular development; ETV2 binds conserved Ets sites in the FLI1 promoter to govern FLI1 expression; once ETV2 is downregulated at midgestation, FLI1 replaces ETV2 at its own promoter (positive autoregulation) and at promoters of other endothelial genes including Tie2, sustaining endothelial cell survival and vascular integrity.","method":"ChIP, promoter binding assays, loss- and gain-of-function experiments in mouse embryos and cell lines","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 — ChIP plus genetic loss/gain-of-function with molecular and vascular phenotype readouts","pmids":["24727028"],"is_preprint":false},{"year":2015,"finding":"EWS-FLI1 interacts with spliceosomal complex proteins (DDX5, hnRNP K, PRPF6, RNA helicase A) and regulates alternative splicing of cancer-relevant genes (CLK1, CASP3, PPFIBP1, TERT); EWS-FLI1 RNA-binding motifs cluster near intron-exon boundaries (CLIP-seq); the small molecule YK-4-279 disrupts EWS-FLI1 interaction with DDX5 and RHA, altering RNA splicing ratios.","method":"CLIP-seq, exon array, RNA-seq, co-immunoprecipitation, small molecule inhibitor (YK-4-279)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (CLIP-seq, co-IP, exon array, RNA-seq) with pharmacological validation","pmids":["25737553"],"is_preprint":false},{"year":2015,"finding":"EWS-FLI1 reduces RHA helicase activity in a dose-dependent manner without affecting intrinsic ATPase activity; (S)-YK-4-279 reverses this inhibition; EWS-FLI1 has a novel RNA-binding property that alters the RNA-binding profile of both EWS-FLI1 and RHA.","method":"In vitro helicase activity assay, ATPase assay, enantiomer-specific small molecule reversal, RNA binding assays","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzymatic assay with dose-response and enantiomer-specific pharmacological reversal","pmids":["25564528"],"is_preprint":false},{"year":2015,"finding":"Crystal structures of FLI1 DBD alone and in complex with GGAA-containing DNA reveal a previously unrecognized helix-swapped homodimer stabilized by hydrophobic interactions centered on Phe362; Phe362Ala mutation disrupts dimerization without perturbing structure or DNA binding, indicating dimerization is distinct from DNA binding function.","method":"X-ray crystallography, solution dimerization assays, site-directed mutagenesis (Phe362Ala)","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — crystal structure combined with mutagenesis validating functional dimerization interface","pmids":["26618620"],"is_preprint":false},{"year":2016,"finding":"Crystal structures of mithramycin analogues (MTM SA-Trp, MTM SA-Phe) bound to DNA containing GGAA (a FLI1 binding site) reveal minor-groove binding that perturbs FLI1 bound in the major groove; NMR demonstrates formation of a ternary FLI1-DNA-MTM complex on a single GGAA site; sub-micromolar MTM stabilizes FLI1-DNA complex on GGAA repeats.","method":"X-ray crystallography, NMR, electromobility shift assay","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 — structural determination plus NMR validation of ternary complex","pmids":["27587584"],"is_preprint":false},{"year":2016,"finding":"FLI1 directly binds the CXCL2 promoter (established by ChIP) and drives its transcription dose-dependently in endothelial cells; both FLI1 and NF-κB p65 additively regulate CXCL2 activation.","method":"ChIP, siRNA knockdown, transient transfection reporter assays","journal":"Molecular immunology","confidence":"High","confidence_rationale":"Tier 2 — ChIP plus siRNA knockdown and reporter assays with dose-dependent relationship","pmids":["27889620"],"is_preprint":false},{"year":2016,"finding":"Acetylation of FLI1 by p300/CBP and PCAF at the C-terminal DNA-binding domain increases its DNA-binding activity in vitro and increases EWS-FLI1 transcriptional activity; HDAC inhibitor treatment increases EWS-FLI1 transcriptional activity.","method":"In vitro acetylation assay, EMSA, co-transfection with acetyltransferases (PCAF, p300/CBP), HDI treatment","journal":"Frontiers in oncology","confidence":"Medium","confidence_rationale":"Tier 1 in vitro but full-length acetylation in cells remained unclear per authors","pmids":["22973553"],"is_preprint":false},{"year":2016,"finding":"FLI1-driven activation of the G-CSF promoter is regulated by acetylation: mutation of a known FLI1 acetylation site increases G-CSF promoter activation, while the acetyltransferases p300/CBP and PCAF decrease FLI1-specific G-CSF promoter transactivation; FLI1 DNA-binding domain mutation reduces transactivation by 94%.","method":"ChIP, transient transfection reporter assays, acetyltransferase co-transfection, site-directed mutagenesis of acetylation and DNA-binding sites","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — ChIP, reporter assays with multiple mutagenesis strategies and acetyltransferase overexpression","pmids":["27431361"],"is_preprint":false},{"year":2017,"finding":"FLI1 deficiency in endothelial cells promotes migration, proliferation, and cell survival, while abating tube formation; FLI1 deficiency activates integrin αvβ3/αvβ5-mediated TGFβ activation and triggers endothelial-to-mesenchymal transition.","method":"siRNA knockdown, scratch/transwell migration assays, BrdU proliferation assay, flow cytometry apoptosis assay, Matrigel tube formation, ChIP for TGFβ/integrin promoters","journal":"Experimental dermatology / Arthritis & rheumatology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal cell-based assays with ChIP for target gene binding","pmids":["28370536","25385187"],"is_preprint":false},{"year":2017,"finding":"FLI1 directly regulates AIRE expression in epithelial cells; keratin 14-specific Fli1 knockout mice spontaneously develop dermal and esophageal fibrosis with epithelial activation and systemic autoimmunity including thymic defects.","method":"Keratin 14-Cre conditional knockout, ChIP for Aire promoter, gene silencing in keratinocytes","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with defined phenotype and ChIP validation of direct target","pmids":["28232470"],"is_preprint":false},{"year":2017,"finding":"Combined knockdown of ERG and FLI1 in endothelial cells induces endothelial-to-mesenchymal transition coupled with dynamic epigenetic changes; genome-wide analysis shows ERG and FLI1 are critical transcriptional activators of EC-specific genes; microRNA-126 partially mediates EndMT blockade downstream of ERG/FLI1; ERG and FLI1 expression is downregulated in tumor-associated ECs by soluble factors.","method":"siRNA knockdown, genome-wide expression profiling, ATAC-seq/epigenomic analysis, miR-126 functional assays","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 — genome-wide epigenomic analyses with knockdown and downstream pathway validation","pmids":["30500808"],"is_preprint":false},{"year":2018,"finding":"A circular RNA (FECR1) derived from FLI1 exons 4-2-3 activates FLI1 expression via a positive feedback loop: FECR1 binds the FLI1 promoter in cis and recruits TET1 demethylase to induce DNA hypomethylation; FECR1 also binds and downregulates DNMT1 in trans, cooperatively maintaining FLI1 promoter hypomethylation.","method":"CRISPR-Cas9-guided chromatin immunoprecipitation, RIP assay, bisulfite sequencing, overexpression/knockdown, invasion assays","journal":"Genome biology","confidence":"High","confidence_rationale":"Tier 2 — CRISPR-guided ChIP, RIP, and methylation assays with functional invasion readout","pmids":["30537986"],"is_preprint":false},{"year":2019,"finding":"SPOP E3 ubiquitin ligase and OTUD7A deubiquitinase control EWS-FLI1 protein stability: casein kinase 1-mediated phosphorylation of the VTSSS degron in the FLI1 domain enhances SPOP-mediated degradation of EWS-FLI1; OTUD7A deubiquitinates and stabilizes EWS-FLI1; depletion of OTUD7A reduces EWS-FLI1 abundance and impedes Ewing sarcoma growth in vitro and in vivo.","method":"Co-immunoprecipitation, ubiquitination assays, OTUD7A knockdown, phosphodegron mutagenesis, xenograft mouse model","journal":"Advanced science","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP, ubiquitination assays with domain mutagenesis, and in vivo validation","pmids":["34060252"],"is_preprint":false},{"year":2019,"finding":"USP19 deubiquitinase stabilizes EWS-FLI1 by binding the N-terminal EWS region; depletion of USP19 reduces EWS-FLI1 protein levels; this stabilization is specific to the fusion protein (not wild-type FLI1 or EWSR1 alone); stable USP19 knockdown decreases growth and colony formation in vitro and delays tumor growth in vivo.","method":"siRNA screen, co-immunoprecipitation, shRNA knockdown, xenograft model","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 — co-IP mapping interaction domain, deubiquitinase-specific knockdown with in vitro and in vivo phenotypes","pmids":["30700749"],"is_preprint":false},{"year":2021,"finding":"FLI1 restrains CD8+ effector T cell (TEFF) differentiation by binding cis-regulatory elements of effector-associated genes; loss of FLI1 increases chromatin accessibility at ETS:RUNX motifs, allowing Runx3-driven TEFF biology; genetic deletion of Fli1 enhances TEFF responses without compromising memory or exhaustion precursors, improving protection against infections and tumors.","method":"In vivo CRISPR screen, genetic deletion, ATAC-seq, ChIP-seq, infection/tumor challenge models","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — in vivo CRISPR screen with genetic deletion, chromatin accessibility profiling, and multiple functional in vivo models","pmids":["33636129"],"is_preprint":false},{"year":2021,"finding":"EWS-FLI1 low-complexity (LC) domain is required for assembly into protein granules in Ewing sarcoma cells; EWS-FLI1 can self-assemble via its LC domain and bind RNA Pol II; EWSR1 knockdown affects many EWS-FLI1-regulated transcripts, suggesting co-assembly in shared complexes.","method":"siRNA knockdown, RNA-seq, cross-linking-based protein assembly assay, co-immunoprecipitation","journal":"RNA","confidence":"Medium","confidence_rationale":"Tier 2 — cross-linking assembly assay and co-IP but protein granule assembly model requires further structural validation","pmids":["34035145"],"is_preprint":false},{"year":2022,"finding":"Fli1 restricts NK cell memory precursor (MP) formation by regulating the pro-apoptotic factor Bim; Fli1 is induced by STAT5 signaling in NK cells; MP NK cells have a core epigenetic signature enriched in ETS1 and Fli1 DNA-binding motifs; Fli1 induction in early effector NK cells increases Bim levels and limits NK cell survival during contraction.","method":"Single-cell RNA-seq, ATAC-seq, ex vivo STAT5 stimulation, genetic Fli1 manipulation, viral infection model","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — scRNA-seq, ATAC-seq, and functional ex vivo/in vivo NK cell experiments defining pathway","pmids":["35288713"],"is_preprint":false},{"year":2023,"finding":"ETV6 competes with EWS-FLI1 for binding at select DNA elements enriched for short GGAA repeat sequences; inactivating ETV6 allows EWS-FLI1 to hyper-activate these cis-elements, promoting mesenchymal differentiation via SOX11 as a key downstream target; a dominant-interfering ETV6 peptide squelches ETV6 and suppresses Ewing sarcoma growth in vivo.","method":"Domain-focused CRISPR screen, biochemical competition assays, epigenomics (ChIP-seq), dominant-interfering peptide, in vivo xenograft model","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 — CRISPR screen with epigenomic and biochemical validation plus in vivo efficacy","pmids":["36658219"],"is_preprint":false},{"year":2024,"finding":"FLI1 orchestrates IDO1 transcription in response to IFN-γ by facilitating recruitment of CBP and STAT1 and increasing chromatin accessibility at the IDO1 locus; this drives increased kynurenine synthesis leading to CD8+ T cell exhaustion and Treg differentiation; pharmacological FLI1 inhibition blocks the CBP/STAT1-IDO1-kynurenine axis.","method":"siRNA/shRNA knockdown, ChIP, ATAC-seq, co-immunoprecipitation of FLI1-CBP-STAT1, pharmacological inhibition, T cell functional assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — ChIP, ATAC-seq, co-IP, and pharmacological inhibition with functional immune readouts","pmids":["38816360"],"is_preprint":false},{"year":2002,"finding":"IL-6 induces Fli-1 expression via STAT3; this induction is blocked by the JAK inhibitor AG490 and by dominant-negative STAT3, establishing a JAK-STAT3-FLI1 signaling axis.","method":"Pharmacological inhibition (AG490), dominant-negative STAT3 transfection, Western blot/RT-PCR for FLI1 induction","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 — single lab, pharmacological and dominant-negative epistasis without direct promoter binding shown","pmids":["11890706"],"is_preprint":false},{"year":2003,"finding":"FLI1-transformed erythroblasts upregulate SLAP, which forms a specific complex with EpoR; SLAP constitutive expression impairs hemoglobinization and inhibits Epo-dependent STAT5 activation and BCL-X upregulation, establishing FLI1 inhibition of erythroid differentiation through SLAP-mediated EpoR signaling interference.","method":"Co-immunoprecipitation, retroviral overexpression, Epo differentiation assays, Western blot for STAT5 phosphorylation","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — co-IP establishing complex plus functional assays with defined signaling readouts","pmids":["12946994"],"is_preprint":false},{"year":2012,"finding":"EWS-FLI1 directly activates transcription of PRKCB (PKC-β), which in turn phosphorylates histone H3T6 to maintain H3K4 trimethylation at gene promoters in Ewing sarcoma; PKC-β loss induces apoptosis and prevents tumor growth in vivo.","method":"ChIP, siRNA knockdown, gene expression profiling, xenograft tumor model, histone modification assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — ChIP demonstrating direct regulation, histone modification assay, and in vivo validation","pmids":["22930730"],"is_preprint":false},{"year":2016,"finding":"FLI1 directly binds the promoters of SHIP-1 and GATA-1 target genes; anti-Fli-1 drug treatment inhibits FLI1 DNA binding to these targets; a FLI1-miR-145 autoregulatory loop exists where FLI1 represses miR-145, and diterpenoid inhibitors relieve this repression to further downregulate FLI1.","method":"ChIP, DNA binding assays, promoter reporter assays, miR-145 functional studies, in vivo erythroleukemia model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and DNA binding assays with in vivo model, but autoregulatory loop based on correlative and pharmacological data","pmids":["30741932"],"is_preprint":false},{"year":2019,"finding":"Trabectedin evicts the SWI/SNF chromatin-remodeling complex from chromatin and redistributes EWS-FLI1 in the nucleus, leading to increased H3K27me3 and H3K9me3 at EWS-FLI1 target genes and suppression of their expression.","method":"Biochemical chromatin fractionation, ChIP-seq, confocal microscopy, qPCR, Western blot, cell viability assays, in vivo 18F-FLT imaging","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (ChIP-seq, fractionation, imaging) with in vivo validation","pmids":["30723142"],"is_preprint":false},{"year":2020,"finding":"RING1B colocalizes with EWSR1-FLI1 at active enhancers (in addition to its canonical repressive Polycomb function) and is necessary for EWSR1-FLI1 recruitment to enhancers and expression of key EWS-FLI1 target genes; RING1B knockdown impairs tumor xenograft growth.","method":"ChIP-seq, siRNA knockdown, xenograft model, AURKB pharmacological inhibition","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 — genome-wide ChIP-seq demonstrating co-occupancy with functional knockdown and in vivo validation","pmids":["33097530"],"is_preprint":false},{"year":2021,"finding":"YAP binds TEAD1 to inhibit FLI1 expression during endothelial cell differentiation from pluripotent stem cells; FLI1 overexpression rescues YAP overexpression-mediated inhibition of EC differentiation, placing FLI1 downstream of YAP/TEAD1 in the EC commitment pathway.","method":"Luciferase reporter assay for FLI1 promoter, siRNA knockdown of YAP, FLI1 overexpression rescue, microarray analysis","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 3 — single lab, luciferase and rescue assays without direct YAP-TEAD1 binding to FLI1 promoter confirmed by ChIP","pmids":["34666000"],"is_preprint":false},{"year":2022,"finding":"FLI1 regulates expression of claudin-5, occludin, and ZO-1 in glioma endothelial cells by binding to their promoter regions, controlling blood-tumour barrier permeability; this is upstream of a miR-194-5p/FLI1 axis.","method":"Luciferase assay (miR-194-5p target validation), siRNA knockdown, promoter binding assays, barrier permeability assay","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 3 — promoter binding assays and functional permeability readout, single lab","pmids":["31654502"],"is_preprint":false}],"current_model":"FLI1 is an ETS family transcription factor that binds GGA(A/T)-containing DNA sequences as a monomer or helix-swapped homodimer to activate or repress target genes (including COL1A2, CCL5, CXCL2, G-CSF, MDM2, LMO2, AIRE, IDO1, and tight junction proteins) in endothelial cells, hematopoietic stem cells, megakaryocytes, T cells, and NK cells; it participates in a recursive triad network with GATA2 and SCL during hematopoietic specification, is activated downstream of ETV2 (which it then replaces via positive autoregulation) in vascular development, cross-antagonizes EKLF to control erythroid vs. megakaryocyte fate decisions, and is subject to post-translational regulation including acetylation (by p300/CBP/PCAF, enhancing DNA binding), casein kinase 1-mediated phosphorylation (enabling SPOP-mediated ubiquitin-proteasome degradation), and stabilization by the deubiquitinases OTUD7A and USP19; in its oncogenic EWS-FLI1 fusion form, the protein functions as an aberrant transcriptional activator and splicing regulator through interactions with RHA (whose helicase activity it inhibits) and the SWI/SNF complex, acting on GGAA microsatellite enhancers and classical ETS promoter elements to drive Ewing sarcoma."},"narrative":{"teleology":[{"year":1993,"claim":"Establishing FLI1 as a sequence-specific DNA-binding transcriptional activator with modular activation domains resolved its basic molecular function and revealed an N-terminal auto-inhibitory domain whose removal (as in EWS-FLI1) derepresses the C-terminal activation domain.","evidence":"DNA binding assays, methylation protection, co-transfection reporter assays, and deletion analysis in cell lines","pmids":["8449942","7503813"],"confidence":"High","gaps":["Full-length structural basis of auto-inhibition not resolved","Physiological contexts activating the C-terminal domain in wild-type FLI1 unknown"]},{"year":1995,"claim":"Demonstrating that EWS-FLI1 transformation requires both the EWS activation domain and FLI1 DNA-binding domain — and cooperates with other transcription factors — established the oncogenic fusion as a gain-of-function transcriptional activator rather than a simple deregulation of FLI1.","evidence":"Soft agar colony assays with systematic deletion and domain-swap mutants in NIH3T3 cells","pmids":["7845667"],"confidence":"High","gaps":["Cooperating transcription factors not identified","Transformation-specific versus transactivation functions map to different EWS sub-domains but downstream targets not defined"]},{"year":1998,"claim":"Discovery that TEL/ETV6 directly binds FLI1 and inhibits its megakaryocytic transactivation introduced the concept of ETS-family cross-regulation of FLI1 activity, later extended to ETV6 competition with EWS-FLI1 at GGAA repeats.","evidence":"Yeast two-hybrid, in vitro/in vivo binding, and reporter assays with deletion mutants","pmids":["9651344"],"confidence":"High","gaps":["In vivo relevance in megakaryopoiesis not shown","Stoichiometry of TEL-FLI1 complex undetermined"]},{"year":2001,"claim":"Identifying FLI1 as a direct repressor of COL1A2 via DNA binding and Sp1 interaction established its role in extracellular matrix gene regulation and linked FLI1 to fibrosis-related biology.","evidence":"Reporter assays, in vitro binding, dominant-negative and DNA-binding mutants in dermal fibroblasts","pmids":["11278621"],"confidence":"High","gaps":["Co-repressor identity not determined","In vivo fibrosis phenotype not tested at this stage"]},{"year":2003,"claim":"The cross-antagonism between FLI1 and EKLF — where FLI1 represses erythroid β-globin transcription while EKLF represses FLI1-driven megakaryocytic GPIX — provided a molecular switch model for erythroid versus megakaryocytic fate decisions.","evidence":"Reciprocal reporter assays, co-immunoprecipitation, and Gal4 fusion domain mapping","pmids":["12556498"],"confidence":"High","gaps":["In vivo lineage commitment phenotype of the cross-antagonism not directly tested","Quantitative threshold for fate switching unknown"]},{"year":2005,"claim":"ChIP-validated binding of FLI1 to the MDM2 and LMO2 promoters expanded its direct target repertoire to include a p53 pathway regulator and a key hematopoietic/endothelial transcription factor.","evidence":"ChIP, in vitro binding, reporter assays, and transgenic mouse enhancer analysis","pmids":["15592502","15994290"],"confidence":"High","gaps":["Whether FLI1-MDM2-p53 axis operates in normal hematopoiesis versus only erythroleukemia not resolved"]},{"year":2007,"claim":"Demonstration that FLI1, GATA2, and SCL co-occupy each other's enhancers in HSCs established a recursively wired triad circuit as the regulatory kernel of hematopoietic specification.","evidence":"ChIP across HSCs, fetal liver, and hemangioblast equivalents; enhancer-reporter and transgenic analysis","pmids":["17962413"],"confidence":"High","gaps":["Order of assembly and temporal hierarchy among the three factors not resolved","Functional necessity of recursive wiring versus simple co-regulation not tested by enhancer mutation"]},{"year":2014,"claim":"Placing FLI1 downstream of ETV2 and showing that FLI1 replaces ETV2 at its own promoter via positive autoregulation resolved how endothelial gene programs persist after ETV2 downregulation at midgestation.","evidence":"ChIP and loss/gain-of-function in mouse embryos and endothelial cell lines","pmids":["24727028"],"confidence":"High","gaps":["Whether FLI1 is sufficient alone or requires ERG redundancy for endothelial maintenance in vivo"]},{"year":2015,"claim":"Crystal structures of the FLI1 DNA-binding domain revealed a helix-swapped homodimer mediated by Phe362, separating dimerization from DNA-binding function and providing a structural framework for understanding FLI1 cooperativity on GGAA repeats.","evidence":"X-ray crystallography of free and DNA-bound FLI1 DBD, Phe362Ala mutagenesis, solution dimerization assays","pmids":["26618620"],"confidence":"High","gaps":["Functional consequence of dimerization for transcription in cells not established","Full-length FLI1 structure unavailable"]},{"year":2015,"claim":"Demonstrating that EWS-FLI1 directly interacts with splicing factors (DDX5, hnRNP K, RHA) via CLIP-seq and regulates alternative splicing established a non-canonical post-transcriptional function for the fusion beyond transcription.","evidence":"CLIP-seq, exon array, RNA-seq, co-IP, and pharmacological disruption with YK-4-279 in Ewing sarcoma cells","pmids":["25737553","25564528"],"confidence":"High","gaps":["Whether wild-type FLI1 has any splicing regulatory activity unknown","Specific RNA targets essential for transformation not defined"]},{"year":2016,"claim":"Showing that p300/CBP/PCAF acetylate FLI1 at its DNA-binding domain to enhance DNA binding, while differentially modulating target gene-specific transactivation (enhancing some targets, reducing G-CSF promoter activity), revealed post-translational fine-tuning of FLI1 function.","evidence":"In vitro acetylation, EMSA, co-transfection with acetyltransferases, and site-directed mutagenesis of acetylation sites","pmids":["22973553","27431361"],"confidence":"High","gaps":["Acetylation site specificity on full-length FLI1 in vivo not fully mapped","Deacetylase(s) opposing this modification not identified"]},{"year":2019,"claim":"Identifying the SPOP E3 ligase (via CK1-phosphorylated VTSSS degron) and OTUD7A/USP19 deubiquitinases as opposing regulators of EWS-FLI1 stability defined the ubiquitin-proteasome axis controlling fusion protein abundance in Ewing sarcoma.","evidence":"Co-IP, ubiquitination assays, phosphodegron mutagenesis, knockdown with in vivo xenograft validation","pmids":["34060252","30700749"],"confidence":"High","gaps":["Whether SPOP-mediated degradation also governs wild-type FLI1 turnover in normal cells unknown","Structural basis of OTUD7A recognition of EWS-FLI1 not resolved"]},{"year":2021,"claim":"An in vivo CRISPR screen identified FLI1 as a restraint on CD8+ T effector differentiation; its deletion increased chromatin accessibility at ETS:RUNX motifs and enhanced anti-tumor and anti-infection immunity without compromising memory, establishing FLI1 as a checkpoint of effector T cell fate.","evidence":"In vivo CRISPR screen, genetic deletion, ATAC-seq, ChIP-seq, infection and tumor challenge models in mice","pmids":["33636129"],"confidence":"High","gaps":["Mechanism by which FLI1 restricts Runx3 access is not structurally resolved","Relevance in human T cells awaits confirmation"]},{"year":2022,"claim":"FLI1 was shown to limit NK cell memory precursor survival by inducing Bim downstream of STAT5, defining a parallel role to its T cell function in restricting lymphocyte effector/memory balance.","evidence":"scRNA-seq, ATAC-seq, STAT5 stimulation, genetic Fli1 manipulation, viral infection model","pmids":["35288713"],"confidence":"High","gaps":["Direct FLI1 binding to Bim regulatory elements not confirmed by ChIP","Whether FLI1 and ETS1 are redundant in NK cells not resolved"]},{"year":2023,"claim":"A CRISPR screen revealed that ETV6 competes with EWS-FLI1 at GGAA repeat enhancers; ETV6 loss hyper-activates EWS-FLI1 at these sites and drives SOX11-mediated mesenchymal differentiation, providing a direct competition mechanism that tunes EWS-FLI1 output.","evidence":"Domain-focused CRISPR screen, biochemical competition, ChIP-seq, dominant-interfering peptide, xenograft model","pmids":["36658219"],"confidence":"High","gaps":["Whether this competition operates at all GGAA microsatellites or only select sites unclear","Structural basis of ETV6–EWS-FLI1 competition not resolved"]},{"year":2024,"claim":"FLI1 was identified as an orchestrator of IFN-γ-induced IDO1 transcription by recruiting CBP and STAT1 and opening chromatin at the IDO1 locus, thereby driving kynurenine-mediated immunosuppression — linking FLI1 to tumor immune evasion.","evidence":"ChIP, ATAC-seq, co-IP of FLI1–CBP–STAT1, pharmacological FLI1 inhibition, T cell functional assays","pmids":["38816360"],"confidence":"High","gaps":["Whether FLI1-IDO1 axis operates across tumor types beyond those studied","Identity of the pharmacological FLI1 inhibitor target specificity not fully characterized"]},{"year":null,"claim":"Key unresolved questions include: the full-length structure of FLI1 (only the DBD is crystallized), the physiological relevance of homodimerization for transcription, whether SPOP-CK1-mediated degradation regulates wild-type FLI1 in normal hematopoiesis, and whether FLI1's restraint on T/NK effector differentiation can be therapeutically exploited without disrupting its essential endothelial and megakaryocytic functions.","evidence":"","pmids":[],"confidence":"Low","gaps":["Full-length FLI1 structure absent","Dimerization function in transcription unresolved","Therapeutic window for FLI1 modulation in immunotherapy undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,7,10,14,18,19,20]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,7,8,10,11,14,15,22,29,33]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,9,18,29,33]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1,7,8,10,11,14,15,22,29,33]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[13,15,25]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[14,29,31,33]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[21,27,28]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[29,25,38]}],"complexes":["FLI1-GATA2-SCL triad","EWS-FLI1–RHA complex","FLI1–Sp1 complex"],"partners":["EKLF","GATA2","SCL","ETV6","SRF","RHA","SPOP","OTUD7A"],"other_free_text":[]},"mechanistic_narrative":"FLI1 is an ETS family transcription factor that governs hematopoietic stem cell specification, megakaryocyte–erythroid lineage commitment, endothelial cell identity, and lymphocyte effector differentiation. It binds GGA(A/T)-containing DNA via its ETS domain — as a monomer or helix-swapped homodimer stabilized by Phe362 — and possesses N-terminal and C-terminal transcriptional activation domains, with the N-terminal region also exerting auto-inhibitory function that is relieved in the oncogenic EWS-FLI1 fusion [PMID:8449942, PMID:7503813, PMID:26618620]. FLI1 participates in a recursive triad with GATA2 and SCL to maintain hematopoietic enhancer networks, cross-antagonizes EKLF to enforce megakaryocytic over erythroid fate, acts downstream of ETV2 with positive autoregulation to sustain endothelial gene programs, and restrains CD8+ T effector and NK memory precursor differentiation by limiting chromatin accessibility at ETS:RUNX-driven effector loci [PMID:17962413, PMID:12556498, PMID:24727028, PMID:33636129, PMID:35288713]. Its stability and activity are modulated by p300/CBP/PCAF-mediated acetylation enhancing DNA binding, casein kinase 1 phosphorylation enabling SPOP-dependent proteasomal degradation, and OTUD7A/USP19-mediated deubiquitination; in Ewing sarcoma, the EWS-FLI1 fusion acts as an aberrant transcriptional activator at GGAA microsatellite enhancers and additionally functions as a splicing regulator through interactions with RHA and DDX5 [PMID:27431361, PMID:34060252, PMID:30700749, PMID:16740692, PMID:25737553]."},"prefetch_data":{"uniprot":{"accession":"Q01543","full_name":"Friend leukemia integration 1 transcription factor","aliases":["Proto-oncogene Fli-1","Transcription factor ERGB"],"length_aa":452,"mass_kda":51.0,"function":"Sequence-specific transcriptional activator (PubMed:24100448, PubMed:26316623, PubMed:28255014). Recognizes the DNA sequence 5'-C[CA]GGAAGT-3'","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q01543/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FLI1","classification":"Not Classified","n_dependent_lines":68,"n_total_lines":1208,"dependency_fraction":0.056291390728476824},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FLI1","total_profiled":1310},"omim":[{"mim_id":"620491","title":"MATURIN, NEURAL PROGENITOR DIFFERENTIATION REGULATOR HOMOLOG; MTURN","url":"https://www.omim.org/entry/620491"},{"mim_id":"617443","title":"BLEEDING DISORDER, PLATELET-TYPE, 21; BDPLT21","url":"https://www.omim.org/entry/617443"},{"mim_id":"616492","title":"EWING SARCOMA-ASSOCIATED TRANSCRIPT 1, NONCODING; EWSAT1","url":"https://www.omim.org/entry/616492"},{"mim_id":"615815","title":"SMOOTH MUSCLE- AND ENDOTHELIAL CELL-ENRICHED MIGRATION/DIFFERENTIATION-ASSOCIATED LONG NONCODING RNA; SENCR","url":"https://www.omim.org/entry/615815"},{"mim_id":"612219","title":"EWING SARCOMA; ES","url":"https://www.omim.org/entry/612219"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nuclear bodies","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":65.9}],"url":"https://www.proteinatlas.org/search/FLI1"},"hgnc":{"alias_symbol":["SIC-1","EWSR2","FLI-1"],"prev_symbol":[]},"alphafold":{"accession":"Q01543","domains":[{"cath_id":"1.10.150.50","chopping":"125-200","consensus_level":"high","plddt":88.0053,"start":125,"end":200},{"cath_id":"1.10.10.10","chopping":"274-368","consensus_level":"high","plddt":92.0366,"start":274,"end":368}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q01543","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q01543-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q01543-F1-predicted_aligned_error_v6.png","plddt_mean":63.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FLI1","jax_strain_url":"https://www.jax.org/strain/search?query=FLI1"},"sequence":{"accession":"Q01543","fasta_url":"https://rest.uniprot.org/uniprotkb/Q01543.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q01543/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q01543"}},"corpus_meta":[{"pmid":"16234507","id":"PMC_16234507","title":"Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues.","date":"2005","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/16234507","citation_count":661,"is_preprint":false},{"pmid":"30537986","id":"PMC_30537986","title":"A novel FLI1 exonic circular RNA promotes metastasis in breast cancer by coordinately regulating TET1 and DNMT1.","date":"2018","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/30537986","citation_count":352,"is_preprint":false},{"pmid":"29513652","id":"PMC_29513652","title":"EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.","date":"2018","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/29513652","citation_count":254,"is_preprint":false},{"pmid":"9388225","id":"PMC_9388225","title":"The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9388225","citation_count":200,"is_preprint":false},{"pmid":"11474291","id":"PMC_11474291","title":"Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics.","date":"2001","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11474291","citation_count":185,"is_preprint":false},{"pmid":"17962413","id":"PMC_17962413","title":"Gata2, Fli1, and Scl form a recursively wired gene-regulatory circuit during early hematopoietic development.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17962413","citation_count":183,"is_preprint":false},{"pmid":"33636129","id":"PMC_33636129","title":"In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33636129","citation_count":166,"is_preprint":false},{"pmid":"7845667","id":"PMC_7845667","title":"Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene.","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7845667","citation_count":164,"is_preprint":false},{"pmid":"7503813","id":"PMC_7503813","title":"EWS/Fli-1 chimeric protein is a transcriptional activator.","date":"1993","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7503813","citation_count":159,"is_preprint":false},{"pmid":"11278621","id":"PMC_11278621","title":"Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278621","citation_count":144,"is_preprint":false},{"pmid":"8040301","id":"PMC_8040301","title":"EWS-erg and EWS-Fli1 fusion transcripts in Ewing's sarcoma and primitive neuroectodermal tumors with variant translocations.","date":"1994","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/8040301","citation_count":139,"is_preprint":false},{"pmid":"9052984","id":"PMC_9052984","title":"EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro.","date":"1996","source":"Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/9052984","citation_count":124,"is_preprint":false},{"pmid":"9651344","id":"PMC_9651344","title":"The ets family member Tel binds to the Fli-1 oncoprotein and inhibits its transcriptional activity.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9651344","citation_count":122,"is_preprint":false},{"pmid":"25737553","id":"PMC_25737553","title":"Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25737553","citation_count":121,"is_preprint":false},{"pmid":"20547696","id":"PMC_20547696","title":"Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.","date":"2010","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/20547696","citation_count":120,"is_preprint":false},{"pmid":"12556498","id":"PMC_12556498","title":"Functional cross-antagonism between transcription factors FLI-1 and EKLF.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12556498","citation_count":114,"is_preprint":false},{"pmid":"25504335","id":"PMC_25504335","title":"Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25504335","citation_count":114,"is_preprint":false},{"pmid":"24909161","id":"PMC_24909161","title":"The ets transcription factor Fli-1 in development, cancer and disease.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24909161","citation_count":113,"is_preprint":false},{"pmid":"16740692","id":"PMC_16740692","title":"Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16740692","citation_count":112,"is_preprint":false},{"pmid":"10102630","id":"PMC_10102630","title":"FLI-1 inhibits differentiation and induces proliferation of primary erythroblasts.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10102630","citation_count":90,"is_preprint":false},{"pmid":"8449942","id":"PMC_8449942","title":"Characterization of the ets oncogene family member, fli-1.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8449942","citation_count":83,"is_preprint":false},{"pmid":"15183454","id":"PMC_15183454","title":"Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro.","date":"2004","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/15183454","citation_count":82,"is_preprint":false},{"pmid":"17875932","id":"PMC_17875932","title":"EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17875932","citation_count":79,"is_preprint":false},{"pmid":"25385187","id":"PMC_25385187","title":"Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice.","date":"2015","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/25385187","citation_count":77,"is_preprint":false},{"pmid":"16556028","id":"PMC_16556028","title":"Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.","date":"2005","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16556028","citation_count":72,"is_preprint":false},{"pmid":"9049825","id":"PMC_9049825","title":"Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides.","date":"1997","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/9049825","citation_count":70,"is_preprint":false},{"pmid":"28232470","id":"PMC_28232470","title":"Epithelial Fli1 deficiency drives systemic autoimmunity and fibrosis: Possible roles in scleroderma.","date":"2017","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28232470","citation_count":67,"is_preprint":false},{"pmid":"30500808","id":"PMC_30500808","title":"Downregulation of ERG and FLI1 expression in endothelial cells triggers endothelial-to-mesenchymal transition.","date":"2018","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30500808","citation_count":61,"is_preprint":false},{"pmid":"9242212","id":"PMC_9242212","title":"Multiple chromosomal mechanisms generate an EWS/FLI1 or an EWS/ERG fusion gene in Ewing tumors.","date":"1997","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/9242212","citation_count":60,"is_preprint":false},{"pmid":"34060252","id":"PMC_34060252","title":"SPOP and OTUD7A Control EWS-FLI1 Protein Stability to Govern Ewing Sarcoma Growth.","date":"2021","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/34060252","citation_count":59,"is_preprint":false},{"pmid":"12509448","id":"PMC_12509448","title":"Alteration of mesodermal cell differentiation by EWS/FLI-1, the oncogene implicated in Ewing's sarcoma.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12509448","citation_count":57,"is_preprint":false},{"pmid":"22930730","id":"PMC_22930730","title":"Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-β abolishes ewing sarcoma growth.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22930730","citation_count":55,"is_preprint":false},{"pmid":"11553628","id":"PMC_11553628","title":"DNA binding domain-independent pathways are involved in EWS/FLI1-mediated oncogenesis.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11553628","citation_count":53,"is_preprint":false},{"pmid":"15491164","id":"PMC_15491164","title":"Recombinant EWS-FLI1 oncoprotein activates transcription.","date":"2004","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15491164","citation_count":51,"is_preprint":false},{"pmid":"15994290","id":"PMC_15994290","title":"Fli1, Elf1, and Ets1 regulate the proximal promoter of the LMO2 gene in endothelial cells.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15994290","citation_count":51,"is_preprint":false},{"pmid":"26258070","id":"PMC_26258070","title":"EWS/FLI1 Target Genes and Therapeutic Opportunities in Ewing Sarcoma.","date":"2015","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26258070","citation_count":49,"is_preprint":false},{"pmid":"20156317","id":"PMC_20156317","title":"Downstream EWS/FLI1 - upstream Ewing's sarcoma.","date":"2010","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20156317","citation_count":49,"is_preprint":false},{"pmid":"28671673","id":"PMC_28671673","title":"EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28671673","citation_count":48,"is_preprint":false},{"pmid":"17121899","id":"PMC_17121899","title":"Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma.","date":"2006","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17121899","citation_count":48,"is_preprint":false},{"pmid":"23926301","id":"PMC_23926301","title":"Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23926301","citation_count":48,"is_preprint":false},{"pmid":"30723142","id":"PMC_30723142","title":"Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30723142","citation_count":45,"is_preprint":false},{"pmid":"19074838","id":"PMC_19074838","title":"EWS-Fli1 up-regulates expression of the Aurora A and Aurora B kinases.","date":"2008","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/19074838","citation_count":43,"is_preprint":false},{"pmid":"22829238","id":"PMC_22829238","title":"Drug-mediated inhibition of Fli-1 for the treatment of leukemia.","date":"2012","source":"Blood cancer journal","url":"https://pubmed.ncbi.nlm.nih.gov/22829238","citation_count":43,"is_preprint":false},{"pmid":"8604338","id":"PMC_8604338","title":"SRE elements are binding sites for the fusion protein EWS-FLI-1.","date":"1996","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/8604338","citation_count":42,"is_preprint":false},{"pmid":"20103643","id":"PMC_20103643","title":"EWS/FLI1 oncogene activates caspase 3 transcription and triggers apoptosis in vivo.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20103643","citation_count":42,"is_preprint":false},{"pmid":"36658219","id":"PMC_36658219","title":"ETV6 dependency in Ewing sarcoma by antagonism of EWS-FLI1-mediated enhancer activation.","date":"2023","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/36658219","citation_count":40,"is_preprint":false},{"pmid":"27166877","id":"PMC_27166877","title":"Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.","date":"2016","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/27166877","citation_count":39,"is_preprint":false},{"pmid":"24727028","id":"PMC_24727028","title":"Fli1 acts downstream of Etv2 to govern cell survival and vascular homeostasis via positive autoregulation.","date":"2014","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/24727028","citation_count":38,"is_preprint":false},{"pmid":"25564528","id":"PMC_25564528","title":"RNA helicase A activity is inhibited by oncogenic transcription factor EWS-FLI1.","date":"2015","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/25564528","citation_count":37,"is_preprint":false},{"pmid":"25098295","id":"PMC_25098295","title":"The Fli-1 transcription factor regulates the expression of CCL5/RANTES.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25098295","citation_count":36,"is_preprint":false},{"pmid":"38816360","id":"PMC_38816360","title":"FLI1 promotes IFN-γ-induced kynurenine production to impair anti-tumor immunity.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38816360","citation_count":36,"is_preprint":false},{"pmid":"12432241","id":"PMC_12432241","title":"EWS-FLI1 and Ewing's sarcoma: recent molecular data and new insights.","date":"2002","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/12432241","citation_count":36,"is_preprint":false},{"pmid":"30741932","id":"PMC_30741932","title":"Identification of diterpenoid compounds that interfere with Fli-1 DNA binding to suppress leukemogenesis.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30741932","citation_count":36,"is_preprint":false},{"pmid":"27889620","id":"PMC_27889620","title":"The Fli-1 transcription factor is a critical regulator for controlling the expression of chemokine C-X-C motif ligand 2 (CXCL2).","date":"2016","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27889620","citation_count":36,"is_preprint":false},{"pmid":"35412146","id":"PMC_35412146","title":"Current insights into the role of Fli-1 in hematopoiesis and malignant transformation.","date":"2022","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/35412146","citation_count":35,"is_preprint":false},{"pmid":"28248553","id":"PMC_28248553","title":"Synergistic Role of Endothelial ERG and FLI1 in Mediating Pulmonary Vascular Homeostasis.","date":"2017","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28248553","citation_count":35,"is_preprint":false},{"pmid":"28255014","id":"PMC_28255014","title":"Macrothrombocytopenia and dense granule deficiency associated with FLI1 variants: ultrastructural and pathogenic features.","date":"2017","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/28255014","citation_count":34,"is_preprint":false},{"pmid":"20731671","id":"PMC_20731671","title":"Impact of Fli-1 transcription factor on autoantibody and lupus nephritis in NZM2410 mice.","date":"2010","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20731671","citation_count":34,"is_preprint":false},{"pmid":"30700749","id":"PMC_30700749","title":"USP19 deubiquitinates EWS-FLI1 to regulate Ewing sarcoma growth.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30700749","citation_count":32,"is_preprint":false},{"pmid":"33080033","id":"PMC_33080033","title":"EWS-FLI1 regulates and cooperates with core regulatory circuitry in Ewing sarcoma.","date":"2020","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/33080033","citation_count":32,"is_preprint":false},{"pmid":"28432223","id":"PMC_28432223","title":"FLI1 level during megakaryopoiesis affects thrombopoiesis and platelet biology.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28432223","citation_count":32,"is_preprint":false},{"pmid":"17453169","id":"PMC_17453169","title":"EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model.","date":"2007","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/17453169","citation_count":32,"is_preprint":false},{"pmid":"27375017","id":"PMC_27375017","title":"EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27375017","citation_count":31,"is_preprint":false},{"pmid":"26961871","id":"PMC_26961871","title":"Englerin A Inhibits EWS-FLI1 DNA Binding in Ewing Sarcoma Cells.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26961871","citation_count":30,"is_preprint":false},{"pmid":"11890706","id":"PMC_11890706","title":"IL-6 induces expression of the Fli-1 proto-oncogene via STAT3.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11890706","citation_count":30,"is_preprint":false},{"pmid":"30387554","id":"PMC_30387554","title":"Novel flavagline-like compounds with potent Fli-1 inhibitory activity suppress diverse types of leukemia.","date":"2018","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/30387554","citation_count":30,"is_preprint":false},{"pmid":"14751824","id":"PMC_14751824","title":"Therapeutic potentialities of EWS-Fli-1 mRNA-targeted vectorized antisense oligonucleotides.","date":"2003","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/14751824","citation_count":30,"is_preprint":false},{"pmid":"28370536","id":"PMC_28370536","title":"The impact of transcription factor Fli1 deficiency on the regulation of angiogenesis.","date":"2017","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/28370536","citation_count":29,"is_preprint":false},{"pmid":"27457419","id":"PMC_27457419","title":"NF-E2, FLI1 and RUNX1 collaborate at areas of dynamic chromatin to activate transcription in mature mouse megakaryocytes.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27457419","citation_count":29,"is_preprint":false},{"pmid":"26055516","id":"PMC_26055516","title":"Epigenetic suppression of Fli1, a potential predisposing factor in the pathogenesis of systemic sclerosis.","date":"2015","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26055516","citation_count":28,"is_preprint":false},{"pmid":"27587584","id":"PMC_27587584","title":"Structures of mithramycin analogues bound to DNA and implications for targeting transcription factor FLI1.","date":"2016","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/27587584","citation_count":28,"is_preprint":false},{"pmid":"15592502","id":"PMC_15592502","title":"Direct transcriptional regulation of MDM2 by Fli-1.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15592502","citation_count":28,"is_preprint":false},{"pmid":"35653119","id":"PMC_35653119","title":"EWS::FLI1 and HOXD13 Control Tumor Cell Plasticity in Ewing Sarcoma.","date":"2022","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/35653119","citation_count":27,"is_preprint":false},{"pmid":"18271016","id":"PMC_18271016","title":"EWS/FLI1 suppresses retinoblastoma protein function and senescence in Ewing's sarcoma cells.","date":"2008","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/18271016","citation_count":27,"is_preprint":false},{"pmid":"33097530","id":"PMC_33097530","title":"RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis.","date":"2020","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/33097530","citation_count":27,"is_preprint":false},{"pmid":"20110178","id":"PMC_20110178","title":"Loss of GATA1 and gain of FLI1 expression during thrombocyte maturation.","date":"2010","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/20110178","citation_count":26,"is_preprint":false},{"pmid":"24124617","id":"PMC_24124617","title":"Ewing sarcoma cells secrete EWS/Fli-1 fusion mRNA via microvesicles.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24124617","citation_count":26,"is_preprint":false},{"pmid":"34359682","id":"PMC_34359682","title":"Therapeutic Potential of EWSR1-FLI1 Inactivation by CRISPR/Cas9 in Ewing Sarcoma.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34359682","citation_count":25,"is_preprint":false},{"pmid":"34035145","id":"PMC_34035145","title":"Fusion protein EWS-FLI1 is incorporated into a protein granule in cells.","date":"2021","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/34035145","citation_count":24,"is_preprint":false},{"pmid":"35038582","id":"PMC_35038582","title":"Suppression of Fli-1 protects against pericyte loss and cognitive deficits in Alzheimer's disease.","date":"2022","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/35038582","citation_count":24,"is_preprint":false},{"pmid":"19642105","id":"PMC_19642105","title":"EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A.","date":"2010","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19642105","citation_count":24,"is_preprint":false},{"pmid":"35288713","id":"PMC_35288713","title":"The transcription factor Fli1 restricts the formation of memory precursor NK cells during viral infection.","date":"2022","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35288713","citation_count":24,"is_preprint":false},{"pmid":"26462019","id":"PMC_26462019","title":"YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26462019","citation_count":23,"is_preprint":false},{"pmid":"36672331","id":"PMC_36672331","title":"Regulation of EWSR1-FLI1 Function by Post-Transcriptional and Post-Translational Modifications.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36672331","citation_count":22,"is_preprint":false},{"pmid":"33234418","id":"PMC_33234418","title":"Emerging role of Fli1 in autoimmune diseases.","date":"2020","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33234418","citation_count":22,"is_preprint":false},{"pmid":"32508810","id":"PMC_32508810","title":"Fli1 Downregulation in Scleroderma Myeloid Cells Has Profibrotic and Proinflammatory Effects.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32508810","citation_count":22,"is_preprint":false},{"pmid":"18692443","id":"PMC_18692443","title":"A role for Fli-1 in B cell proliferation: implications for SLE pathogenesis.","date":"2008","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/18692443","citation_count":22,"is_preprint":false},{"pmid":"27431361","id":"PMC_27431361","title":"Acetylation impacts Fli-1-driven regulation of granulocyte colony stimulating factor.","date":"2016","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27431361","citation_count":21,"is_preprint":false},{"pmid":"36357572","id":"PMC_36357572","title":"Therapeutic targeting the oncogenic driver EWSR1::FLI1 in Ewing sarcoma through inhibition of the FACT complex.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/36357572","citation_count":21,"is_preprint":false},{"pmid":"8679708","id":"PMC_8679708","title":"Characterization of the human and mouse Fli-1 promoter regions.","date":"1996","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/8679708","citation_count":21,"is_preprint":false},{"pmid":"34666000","id":"PMC_34666000","title":"YAP inhibition promotes endothelial cell differentiation from pluripotent stem cell through EC master transcription factor FLI1.","date":"2021","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/34666000","citation_count":20,"is_preprint":false},{"pmid":"31846072","id":"PMC_31846072","title":"The transcription factor FLI1 promotes cancer progression by affecting cell cycle regulation.","date":"2020","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31846072","citation_count":20,"is_preprint":false},{"pmid":"22973553","id":"PMC_22973553","title":"Acetylation Increases EWS-FLI1 DNA Binding and Transcriptional Activity.","date":"2012","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22973553","citation_count":20,"is_preprint":false},{"pmid":"37894854","id":"PMC_37894854","title":"EWS/FLI1 Characterization, Activation, Repression, Target Genes and Therapeutic Opportunities in Ewing Sarcoma.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37894854","citation_count":19,"is_preprint":false},{"pmid":"32210104","id":"PMC_32210104","title":"Fli-1 Activation through Targeted Promoter Activity Regulation Using a Novel 3', 5'-diprenylated Chalcone Inhibits Growth and Metastasis of Prostate Cancer Cells.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32210104","citation_count":19,"is_preprint":false},{"pmid":"12946994","id":"PMC_12946994","title":"Up-regulation of SLAP in FLI-1-transformed erythroblasts interferes with EpoR signaling.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12946994","citation_count":19,"is_preprint":false},{"pmid":"26618620","id":"PMC_26618620","title":"Structural Basis for Dimerization and DNA Binding of Transcription Factor FLI1.","date":"2015","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26618620","citation_count":18,"is_preprint":false},{"pmid":"32164354","id":"PMC_32164354","title":"High Specificity of BCL11B and GLG1 for EWSR1-FLI1 and EWSR1-ERG Positive Ewing Sarcoma.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32164354","citation_count":18,"is_preprint":false},{"pmid":"35500152","id":"PMC_35500152","title":"Super enhancer-LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1.","date":"2022","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/35500152","citation_count":18,"is_preprint":false},{"pmid":"31654502","id":"PMC_31654502","title":"Circular RNA USP1 regulates the permeability of blood-tumour barrier via miR-194-5p/FLI1 axis.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31654502","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50107,"output_tokens":9922,"usd":0.149576},"stage2":{"model":"claude-opus-4-6","input_tokens":13838,"output_tokens":4189,"usd":0.260873},"total_usd":0.410449,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"FLI1 protein binds specific DNA sequences related to ETS-binding sites and functions as a transcriptional activator, with two autonomous transcriptional activation domains (N-terminal and C-terminal regions).\",\n      \"method\": \"DNA binding assays, methylation protection experiments, co-transfection reporter assays, deletion analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple in vitro and functional assays with deletion analysis establishing DNA binding and transactivation\",\n      \"pmids\": [\"8449942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"EWS/FLI1 chimeric fusion protein functions as a transcriptional activator; the EWS domain acts as a modulatory/regulatory domain for the C-terminal transcriptional activation domain of FLI1, with the EWS-FLI1 fusion releasing the C-terminal activation domain from inhibition imposed by the normal FLI1 N-terminal region.\",\n      \"method\": \"Reporter gene assays, deletion analysis, transient transfection\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct functional dissection with deletion mutagenesis and reporter assays\",\n      \"pmids\": [\"7503813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"EWS/FLI1 transformation of NIH3T3 cells requires both EWS and FLI1 sequences; the EWS domain encodes a strong transcriptional activation domain and can be functionally subdivided into a transformation-efficient but low-transactivation domain (A) and a high-transactivation but less-transformation-efficient domain (B); EWS/FLI1 cooperates with other transcription factors to activate reporter genes.\",\n      \"method\": \"Soft agar colony assays, reporter gene transactivation assays, deletion mutant analysis, chimeric construct transfection\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic deletion and domain-swap mutagenesis with functional transformation readout\",\n      \"pmids\": [\"7845667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"EWS-FLI1, but not FLI1, forms a ternary complex on the c-fos serum response element (SRE) by interacting with SRF protein; both FLI1 and EWS-FLI1 interact with SRF in vitro in the absence of DNA; deletion of the N-terminal domain of FLI1 converts it to EWS-FLI1-like behavior, revealing an N-terminal inhibitory domain in normal FLI1.\",\n      \"method\": \"EMSA, GST pull-down, deletion mutagenesis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mutagenesis and pull-down confirming SRF interaction\",\n      \"pmids\": [\"8604338\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"EWS/FLI1 transformation requires the presence of a functional IGF-IR; IGF-IR knockout fibroblasts expressing EWS/FLI1 fail to form soft agar colonies; EWS/FLI1 expression enhances ligand-stimulated IRS-1 phosphorylation, indicating alteration of IGF-IR signaling.\",\n      \"method\": \"Soft agar colony assay using IGF-IR knockout vs. wild-type fibroblasts, IRS-1 phosphorylation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis using knockout cells with defined transformation and signaling readouts\",\n      \"pmids\": [\"9388225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"TEL (ETV6) binds directly to FLI1 via its helix-loop-helix domain and inhibits FLI1-mediated transactivation of megakaryocytic promoters; full inhibition requires the complete TEL molecule including its DNA-binding domain.\",\n      \"method\": \"Yeast two-hybrid screen, in vitro and in vivo binding assays, transient transfection with deletion mutants\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal binding confirmed in vitro and in vivo with functional transactivation assays and deletion analysis\",\n      \"pmids\": [\"9651344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"FLI1 overexpression in primary erythroblasts inhibits apoptosis (correlating with bcl2 upregulation), inhibits terminal differentiation, and induces proliferation; it prevents downregulation of cyclins D2 and D3 during differentiation.\",\n      \"method\": \"Retroviral transduction of primary avian erythroblasts, Epo deprivation/differentiation assays, Western blot for BCL2/cyclins\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — primary cell loss/gain-of-function with multiple molecular readouts\",\n      \"pmids\": [\"10102630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"FLI1 inhibits COL1A2 (collagen alpha2(I)) promoter activity in dermal fibroblasts via direct DNA binding to a critical ETS site and via indirect protein-protein interaction through Sp1; FLI1 competes with ETS-1 at the COL1A2 promoter; an Sp1-FLI1 complex may recruit a co-repressor for maximal inhibition.\",\n      \"method\": \"Stable transfection, reporter/promoter assays, in vitro DNA-protein binding assays, dominant-negative and DNA-binding mutants, Gal4 fusion experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro binding, mutagenesis, and multiple reporter assays with dominant-negative constructs\",\n      \"pmids\": [\"11278621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"FLI1 represses EKLF-dependent beta-globin transcription by using the repression activity of its ETS DNA-binding domain and indirect recruitment to erythroid promoters via protein-protein interaction with EKLF; FLI1 enhances GATA-1 activity but represses EKLF activity; EKLF reciprocally represses FLI1-dependent megakaryocytic GPIX promoter, establishing a cross-antagonism controlling erythroid vs. megakaryocytic fate.\",\n      \"method\": \"Transient transfection reporter assays, co-immunoprecipitation, Gal4 fusion assays, deletion mutant analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal functional assays with multiple promoters, protein interaction studies, and domain-mapping\",\n      \"pmids\": [\"12556498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"EWS/FLI1 blocks myogenic differentiation in C2C12 myoblasts requiring nuclear localization and DNA-binding functions; it suppresses MyoD and myogenin at transcriptional and post-transcriptional levels, and constitutively induces cyclin D1 while decreasing p21(cip1).\",\n      \"method\": \"Retroviral transduction of C2C12 cells, differentiation assays, RT-PCR, Western blot, DNA-binding mutant analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean loss/gain-of-function with DNA-binding domain mutants and defined molecular readouts\",\n      \"pmids\": [\"12509448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"FLI1 directly binds the MDM2 promoter at a consensus ETS binding site in vitro and in vivo, activating MDM2 transcription; FLI1 overexpression correlates with elevated MDM2 and reduced p53 in erythroleukemic tissues.\",\n      \"method\": \"Chromatin immunoprecipitation, in vitro DNA binding assay, reporter gene assay, in vivo tissue correlation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirming in vivo binding plus reporter assay with in vivo correlation\",\n      \"pmids\": [\"15592502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"FLI1, ELF1, and ETS1 bind conserved Ets sites in the LMO2 proximal promoter in vivo in hematopoietic progenitor and endothelial cells, controlling LMO2 transcription; transgenic analysis confirmed this promoter is sufficient for endothelial expression in vivo.\",\n      \"method\": \"ChIP, transient and stable transfection, real-time RT-PCR, transgenic mouse analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo ChIP combined with transgenic validation\",\n      \"pmids\": [\"15994290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"RNA helicase A (RHA) physically binds EWS-FLI1 (residues 630-1020 of RHA); endogenous RHA forms a complex with EWS-FLI1 in ESFT cells; both proteins co-occupy EWS-FLI1 target gene promoters; RHA stimulates EWS-FLI1 transcriptional activity including Id2, and enhances anchorage-independent growth when co-expressed with EWS-FLI1.\",\n      \"method\": \"Phage display screening, GST pull-down, ELISA, co-immunoprecipitation, ChIP, transcriptional reporter assays, soft agar colony assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal binding methods (phage display, GST pulldown, co-IP, ChIP) with functional transcriptional and transformation readouts\",\n      \"pmids\": [\"16740692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"GATA2, FLI1, and SCL/TAL1 form a recursively wired gene-regulatory circuit during hematopoietic specification; each transcription factor binds to the enhancers of the other two (Fli1+12, Gata2-3, Scl+19 enhancers), all of which use Ets/GATA/E-Box motif clusters; these enhancers are co-occupied by all three factors in HSCs, fetal liver, and hemangioblast equivalents.\",\n      \"method\": \"ChIP, enhancer-driven reporter assays, transgenic analysis, conservation analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide ChIP with functional enhancer validation across multiple cell types\",\n      \"pmids\": [\"17962413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FLI1 directly binds Ets-binding sites within the CCL5 promoter and drives its transcription in a dose-dependent manner; mutation of FLI1 DNA-binding domain reduces CCL5 promoter transactivation; ETS1 acts as a dominant-negative for FLI1 at shared CCL5 promoter sites.\",\n      \"method\": \"ChIP, siRNA knockdown, transient transfection reporter assays, site-directed mutagenesis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirming in vivo binding combined with promoter mutation and reporter assays\",\n      \"pmids\": [\"25098295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FLI1 acts downstream of ETV2 in vascular development; ETV2 binds conserved Ets sites in the FLI1 promoter to govern FLI1 expression; once ETV2 is downregulated at midgestation, FLI1 replaces ETV2 at its own promoter (positive autoregulation) and at promoters of other endothelial genes including Tie2, sustaining endothelial cell survival and vascular integrity.\",\n      \"method\": \"ChIP, promoter binding assays, loss- and gain-of-function experiments in mouse embryos and cell lines\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus genetic loss/gain-of-function with molecular and vascular phenotype readouts\",\n      \"pmids\": [\"24727028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"EWS-FLI1 interacts with spliceosomal complex proteins (DDX5, hnRNP K, PRPF6, RNA helicase A) and regulates alternative splicing of cancer-relevant genes (CLK1, CASP3, PPFIBP1, TERT); EWS-FLI1 RNA-binding motifs cluster near intron-exon boundaries (CLIP-seq); the small molecule YK-4-279 disrupts EWS-FLI1 interaction with DDX5 and RHA, altering RNA splicing ratios.\",\n      \"method\": \"CLIP-seq, exon array, RNA-seq, co-immunoprecipitation, small molecule inhibitor (YK-4-279)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (CLIP-seq, co-IP, exon array, RNA-seq) with pharmacological validation\",\n      \"pmids\": [\"25737553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"EWS-FLI1 reduces RHA helicase activity in a dose-dependent manner without affecting intrinsic ATPase activity; (S)-YK-4-279 reverses this inhibition; EWS-FLI1 has a novel RNA-binding property that alters the RNA-binding profile of both EWS-FLI1 and RHA.\",\n      \"method\": \"In vitro helicase activity assay, ATPase assay, enantiomer-specific small molecule reversal, RNA binding assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic assay with dose-response and enantiomer-specific pharmacological reversal\",\n      \"pmids\": [\"25564528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structures of FLI1 DBD alone and in complex with GGAA-containing DNA reveal a previously unrecognized helix-swapped homodimer stabilized by hydrophobic interactions centered on Phe362; Phe362Ala mutation disrupts dimerization without perturbing structure or DNA binding, indicating dimerization is distinct from DNA binding function.\",\n      \"method\": \"X-ray crystallography, solution dimerization assays, site-directed mutagenesis (Phe362Ala)\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure combined with mutagenesis validating functional dimerization interface\",\n      \"pmids\": [\"26618620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Crystal structures of mithramycin analogues (MTM SA-Trp, MTM SA-Phe) bound to DNA containing GGAA (a FLI1 binding site) reveal minor-groove binding that perturbs FLI1 bound in the major groove; NMR demonstrates formation of a ternary FLI1-DNA-MTM complex on a single GGAA site; sub-micromolar MTM stabilizes FLI1-DNA complex on GGAA repeats.\",\n      \"method\": \"X-ray crystallography, NMR, electromobility shift assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structural determination plus NMR validation of ternary complex\",\n      \"pmids\": [\"27587584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FLI1 directly binds the CXCL2 promoter (established by ChIP) and drives its transcription dose-dependently in endothelial cells; both FLI1 and NF-κB p65 additively regulate CXCL2 activation.\",\n      \"method\": \"ChIP, siRNA knockdown, transient transfection reporter assays\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus siRNA knockdown and reporter assays with dose-dependent relationship\",\n      \"pmids\": [\"27889620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Acetylation of FLI1 by p300/CBP and PCAF at the C-terminal DNA-binding domain increases its DNA-binding activity in vitro and increases EWS-FLI1 transcriptional activity; HDAC inhibitor treatment increases EWS-FLI1 transcriptional activity.\",\n      \"method\": \"In vitro acetylation assay, EMSA, co-transfection with acetyltransferases (PCAF, p300/CBP), HDI treatment\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 in vitro but full-length acetylation in cells remained unclear per authors\",\n      \"pmids\": [\"22973553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FLI1-driven activation of the G-CSF promoter is regulated by acetylation: mutation of a known FLI1 acetylation site increases G-CSF promoter activation, while the acetyltransferases p300/CBP and PCAF decrease FLI1-specific G-CSF promoter transactivation; FLI1 DNA-binding domain mutation reduces transactivation by 94%.\",\n      \"method\": \"ChIP, transient transfection reporter assays, acetyltransferase co-transfection, site-directed mutagenesis of acetylation and DNA-binding sites\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP, reporter assays with multiple mutagenesis strategies and acetyltransferase overexpression\",\n      \"pmids\": [\"27431361\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FLI1 deficiency in endothelial cells promotes migration, proliferation, and cell survival, while abating tube formation; FLI1 deficiency activates integrin αvβ3/αvβ5-mediated TGFβ activation and triggers endothelial-to-mesenchymal transition.\",\n      \"method\": \"siRNA knockdown, scratch/transwell migration assays, BrdU proliferation assay, flow cytometry apoptosis assay, Matrigel tube formation, ChIP for TGFβ/integrin promoters\",\n      \"journal\": \"Experimental dermatology / Arthritis & rheumatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal cell-based assays with ChIP for target gene binding\",\n      \"pmids\": [\"28370536\", \"25385187\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FLI1 directly regulates AIRE expression in epithelial cells; keratin 14-specific Fli1 knockout mice spontaneously develop dermal and esophageal fibrosis with epithelial activation and systemic autoimmunity including thymic defects.\",\n      \"method\": \"Keratin 14-Cre conditional knockout, ChIP for Aire promoter, gene silencing in keratinocytes\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with defined phenotype and ChIP validation of direct target\",\n      \"pmids\": [\"28232470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Combined knockdown of ERG and FLI1 in endothelial cells induces endothelial-to-mesenchymal transition coupled with dynamic epigenetic changes; genome-wide analysis shows ERG and FLI1 are critical transcriptional activators of EC-specific genes; microRNA-126 partially mediates EndMT blockade downstream of ERG/FLI1; ERG and FLI1 expression is downregulated in tumor-associated ECs by soluble factors.\",\n      \"method\": \"siRNA knockdown, genome-wide expression profiling, ATAC-seq/epigenomic analysis, miR-126 functional assays\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide epigenomic analyses with knockdown and downstream pathway validation\",\n      \"pmids\": [\"30500808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A circular RNA (FECR1) derived from FLI1 exons 4-2-3 activates FLI1 expression via a positive feedback loop: FECR1 binds the FLI1 promoter in cis and recruits TET1 demethylase to induce DNA hypomethylation; FECR1 also binds and downregulates DNMT1 in trans, cooperatively maintaining FLI1 promoter hypomethylation.\",\n      \"method\": \"CRISPR-Cas9-guided chromatin immunoprecipitation, RIP assay, bisulfite sequencing, overexpression/knockdown, invasion assays\",\n      \"journal\": \"Genome biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR-guided ChIP, RIP, and methylation assays with functional invasion readout\",\n      \"pmids\": [\"30537986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SPOP E3 ubiquitin ligase and OTUD7A deubiquitinase control EWS-FLI1 protein stability: casein kinase 1-mediated phosphorylation of the VTSSS degron in the FLI1 domain enhances SPOP-mediated degradation of EWS-FLI1; OTUD7A deubiquitinates and stabilizes EWS-FLI1; depletion of OTUD7A reduces EWS-FLI1 abundance and impedes Ewing sarcoma growth in vitro and in vivo.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, OTUD7A knockdown, phosphodegron mutagenesis, xenograft mouse model\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP, ubiquitination assays with domain mutagenesis, and in vivo validation\",\n      \"pmids\": [\"34060252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"USP19 deubiquitinase stabilizes EWS-FLI1 by binding the N-terminal EWS region; depletion of USP19 reduces EWS-FLI1 protein levels; this stabilization is specific to the fusion protein (not wild-type FLI1 or EWSR1 alone); stable USP19 knockdown decreases growth and colony formation in vitro and delays tumor growth in vivo.\",\n      \"method\": \"siRNA screen, co-immunoprecipitation, shRNA knockdown, xenograft model\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — co-IP mapping interaction domain, deubiquitinase-specific knockdown with in vitro and in vivo phenotypes\",\n      \"pmids\": [\"30700749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FLI1 restrains CD8+ effector T cell (TEFF) differentiation by binding cis-regulatory elements of effector-associated genes; loss of FLI1 increases chromatin accessibility at ETS:RUNX motifs, allowing Runx3-driven TEFF biology; genetic deletion of Fli1 enhances TEFF responses without compromising memory or exhaustion precursors, improving protection against infections and tumors.\",\n      \"method\": \"In vivo CRISPR screen, genetic deletion, ATAC-seq, ChIP-seq, infection/tumor challenge models\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo CRISPR screen with genetic deletion, chromatin accessibility profiling, and multiple functional in vivo models\",\n      \"pmids\": [\"33636129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"EWS-FLI1 low-complexity (LC) domain is required for assembly into protein granules in Ewing sarcoma cells; EWS-FLI1 can self-assemble via its LC domain and bind RNA Pol II; EWSR1 knockdown affects many EWS-FLI1-regulated transcripts, suggesting co-assembly in shared complexes.\",\n      \"method\": \"siRNA knockdown, RNA-seq, cross-linking-based protein assembly assay, co-immunoprecipitation\",\n      \"journal\": \"RNA\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cross-linking assembly assay and co-IP but protein granule assembly model requires further structural validation\",\n      \"pmids\": [\"34035145\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Fli1 restricts NK cell memory precursor (MP) formation by regulating the pro-apoptotic factor Bim; Fli1 is induced by STAT5 signaling in NK cells; MP NK cells have a core epigenetic signature enriched in ETS1 and Fli1 DNA-binding motifs; Fli1 induction in early effector NK cells increases Bim levels and limits NK cell survival during contraction.\",\n      \"method\": \"Single-cell RNA-seq, ATAC-seq, ex vivo STAT5 stimulation, genetic Fli1 manipulation, viral infection model\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — scRNA-seq, ATAC-seq, and functional ex vivo/in vivo NK cell experiments defining pathway\",\n      \"pmids\": [\"35288713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ETV6 competes with EWS-FLI1 for binding at select DNA elements enriched for short GGAA repeat sequences; inactivating ETV6 allows EWS-FLI1 to hyper-activate these cis-elements, promoting mesenchymal differentiation via SOX11 as a key downstream target; a dominant-interfering ETV6 peptide squelches ETV6 and suppresses Ewing sarcoma growth in vivo.\",\n      \"method\": \"Domain-focused CRISPR screen, biochemical competition assays, epigenomics (ChIP-seq), dominant-interfering peptide, in vivo xenograft model\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR screen with epigenomic and biochemical validation plus in vivo efficacy\",\n      \"pmids\": [\"36658219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FLI1 orchestrates IDO1 transcription in response to IFN-γ by facilitating recruitment of CBP and STAT1 and increasing chromatin accessibility at the IDO1 locus; this drives increased kynurenine synthesis leading to CD8+ T cell exhaustion and Treg differentiation; pharmacological FLI1 inhibition blocks the CBP/STAT1-IDO1-kynurenine axis.\",\n      \"method\": \"siRNA/shRNA knockdown, ChIP, ATAC-seq, co-immunoprecipitation of FLI1-CBP-STAT1, pharmacological inhibition, T cell functional assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP, ATAC-seq, co-IP, and pharmacological inhibition with functional immune readouts\",\n      \"pmids\": [\"38816360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"IL-6 induces Fli-1 expression via STAT3; this induction is blocked by the JAK inhibitor AG490 and by dominant-negative STAT3, establishing a JAK-STAT3-FLI1 signaling axis.\",\n      \"method\": \"Pharmacological inhibition (AG490), dominant-negative STAT3 transfection, Western blot/RT-PCR for FLI1 induction\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, pharmacological and dominant-negative epistasis without direct promoter binding shown\",\n      \"pmids\": [\"11890706\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"FLI1-transformed erythroblasts upregulate SLAP, which forms a specific complex with EpoR; SLAP constitutive expression impairs hemoglobinization and inhibits Epo-dependent STAT5 activation and BCL-X upregulation, establishing FLI1 inhibition of erythroid differentiation through SLAP-mediated EpoR signaling interference.\",\n      \"method\": \"Co-immunoprecipitation, retroviral overexpression, Epo differentiation assays, Western blot for STAT5 phosphorylation\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — co-IP establishing complex plus functional assays with defined signaling readouts\",\n      \"pmids\": [\"12946994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"EWS-FLI1 directly activates transcription of PRKCB (PKC-β), which in turn phosphorylates histone H3T6 to maintain H3K4 trimethylation at gene promoters in Ewing sarcoma; PKC-β loss induces apoptosis and prevents tumor growth in vivo.\",\n      \"method\": \"ChIP, siRNA knockdown, gene expression profiling, xenograft tumor model, histone modification assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrating direct regulation, histone modification assay, and in vivo validation\",\n      \"pmids\": [\"22930730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FLI1 directly binds the promoters of SHIP-1 and GATA-1 target genes; anti-Fli-1 drug treatment inhibits FLI1 DNA binding to these targets; a FLI1-miR-145 autoregulatory loop exists where FLI1 represses miR-145, and diterpenoid inhibitors relieve this repression to further downregulate FLI1.\",\n      \"method\": \"ChIP, DNA binding assays, promoter reporter assays, miR-145 functional studies, in vivo erythroleukemia model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and DNA binding assays with in vivo model, but autoregulatory loop based on correlative and pharmacological data\",\n      \"pmids\": [\"30741932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Trabectedin evicts the SWI/SNF chromatin-remodeling complex from chromatin and redistributes EWS-FLI1 in the nucleus, leading to increased H3K27me3 and H3K9me3 at EWS-FLI1 target genes and suppression of their expression.\",\n      \"method\": \"Biochemical chromatin fractionation, ChIP-seq, confocal microscopy, qPCR, Western blot, cell viability assays, in vivo 18F-FLT imaging\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (ChIP-seq, fractionation, imaging) with in vivo validation\",\n      \"pmids\": [\"30723142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"RING1B colocalizes with EWSR1-FLI1 at active enhancers (in addition to its canonical repressive Polycomb function) and is necessary for EWSR1-FLI1 recruitment to enhancers and expression of key EWS-FLI1 target genes; RING1B knockdown impairs tumor xenograft growth.\",\n      \"method\": \"ChIP-seq, siRNA knockdown, xenograft model, AURKB pharmacological inhibition\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide ChIP-seq demonstrating co-occupancy with functional knockdown and in vivo validation\",\n      \"pmids\": [\"33097530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"YAP binds TEAD1 to inhibit FLI1 expression during endothelial cell differentiation from pluripotent stem cells; FLI1 overexpression rescues YAP overexpression-mediated inhibition of EC differentiation, placing FLI1 downstream of YAP/TEAD1 in the EC commitment pathway.\",\n      \"method\": \"Luciferase reporter assay for FLI1 promoter, siRNA knockdown of YAP, FLI1 overexpression rescue, microarray analysis\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, luciferase and rescue assays without direct YAP-TEAD1 binding to FLI1 promoter confirmed by ChIP\",\n      \"pmids\": [\"34666000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FLI1 regulates expression of claudin-5, occludin, and ZO-1 in glioma endothelial cells by binding to their promoter regions, controlling blood-tumour barrier permeability; this is upstream of a miR-194-5p/FLI1 axis.\",\n      \"method\": \"Luciferase assay (miR-194-5p target validation), siRNA knockdown, promoter binding assays, barrier permeability assay\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — promoter binding assays and functional permeability readout, single lab\",\n      \"pmids\": [\"31654502\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FLI1 is an ETS family transcription factor that binds GGA(A/T)-containing DNA sequences as a monomer or helix-swapped homodimer to activate or repress target genes (including COL1A2, CCL5, CXCL2, G-CSF, MDM2, LMO2, AIRE, IDO1, and tight junction proteins) in endothelial cells, hematopoietic stem cells, megakaryocytes, T cells, and NK cells; it participates in a recursive triad network with GATA2 and SCL during hematopoietic specification, is activated downstream of ETV2 (which it then replaces via positive autoregulation) in vascular development, cross-antagonizes EKLF to control erythroid vs. megakaryocyte fate decisions, and is subject to post-translational regulation including acetylation (by p300/CBP/PCAF, enhancing DNA binding), casein kinase 1-mediated phosphorylation (enabling SPOP-mediated ubiquitin-proteasome degradation), and stabilization by the deubiquitinases OTUD7A and USP19; in its oncogenic EWS-FLI1 fusion form, the protein functions as an aberrant transcriptional activator and splicing regulator through interactions with RHA (whose helicase activity it inhibits) and the SWI/SNF complex, acting on GGAA microsatellite enhancers and classical ETS promoter elements to drive Ewing sarcoma.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"FLI1 is an ETS family transcription factor that governs hematopoietic stem cell specification, megakaryocyte–erythroid lineage commitment, endothelial cell identity, and lymphocyte effector differentiation. It binds GGA(A/T)-containing DNA via its ETS domain — as a monomer or helix-swapped homodimer stabilized by Phe362 — and possesses N-terminal and C-terminal transcriptional activation domains, with the N-terminal region also exerting auto-inhibitory function that is relieved in the oncogenic EWS-FLI1 fusion [PMID:8449942, PMID:7503813, PMID:26618620]. FLI1 participates in a recursive triad with GATA2 and SCL to maintain hematopoietic enhancer networks, cross-antagonizes EKLF to enforce megakaryocytic over erythroid fate, acts downstream of ETV2 with positive autoregulation to sustain endothelial gene programs, and restrains CD8+ T effector and NK memory precursor differentiation by limiting chromatin accessibility at ETS:RUNX-driven effector loci [PMID:17962413, PMID:12556498, PMID:24727028, PMID:33636129, PMID:35288713]. Its stability and activity are modulated by p300/CBP/PCAF-mediated acetylation enhancing DNA binding, casein kinase 1 phosphorylation enabling SPOP-dependent proteasomal degradation, and OTUD7A/USP19-mediated deubiquitination; in Ewing sarcoma, the EWS-FLI1 fusion acts as an aberrant transcriptional activator at GGAA microsatellite enhancers and additionally functions as a splicing regulator through interactions with RHA and DDX5 [PMID:27431361, PMID:34060252, PMID:30700749, PMID:16740692, PMID:25737553].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Establishing FLI1 as a sequence-specific DNA-binding transcriptional activator with modular activation domains resolved its basic molecular function and revealed an N-terminal auto-inhibitory domain whose removal (as in EWS-FLI1) derepresses the C-terminal activation domain.\",\n      \"evidence\": \"DNA binding assays, methylation protection, co-transfection reporter assays, and deletion analysis in cell lines\",\n      \"pmids\": [\"8449942\", \"7503813\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length structural basis of auto-inhibition not resolved\", \"Physiological contexts activating the C-terminal domain in wild-type FLI1 unknown\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Demonstrating that EWS-FLI1 transformation requires both the EWS activation domain and FLI1 DNA-binding domain — and cooperates with other transcription factors — established the oncogenic fusion as a gain-of-function transcriptional activator rather than a simple deregulation of FLI1.\",\n      \"evidence\": \"Soft agar colony assays with systematic deletion and domain-swap mutants in NIH3T3 cells\",\n      \"pmids\": [\"7845667\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cooperating transcription factors not identified\", \"Transformation-specific versus transactivation functions map to different EWS sub-domains but downstream targets not defined\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Discovery that TEL/ETV6 directly binds FLI1 and inhibits its megakaryocytic transactivation introduced the concept of ETS-family cross-regulation of FLI1 activity, later extended to ETV6 competition with EWS-FLI1 at GGAA repeats.\",\n      \"evidence\": \"Yeast two-hybrid, in vitro/in vivo binding, and reporter assays with deletion mutants\",\n      \"pmids\": [\"9651344\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance in megakaryopoiesis not shown\", \"Stoichiometry of TEL-FLI1 complex undetermined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identifying FLI1 as a direct repressor of COL1A2 via DNA binding and Sp1 interaction established its role in extracellular matrix gene regulation and linked FLI1 to fibrosis-related biology.\",\n      \"evidence\": \"Reporter assays, in vitro binding, dominant-negative and DNA-binding mutants in dermal fibroblasts\",\n      \"pmids\": [\"11278621\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-repressor identity not determined\", \"In vivo fibrosis phenotype not tested at this stage\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"The cross-antagonism between FLI1 and EKLF — where FLI1 represses erythroid β-globin transcription while EKLF represses FLI1-driven megakaryocytic GPIX — provided a molecular switch model for erythroid versus megakaryocytic fate decisions.\",\n      \"evidence\": \"Reciprocal reporter assays, co-immunoprecipitation, and Gal4 fusion domain mapping\",\n      \"pmids\": [\"12556498\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo lineage commitment phenotype of the cross-antagonism not directly tested\", \"Quantitative threshold for fate switching unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"ChIP-validated binding of FLI1 to the MDM2 and LMO2 promoters expanded its direct target repertoire to include a p53 pathway regulator and a key hematopoietic/endothelial transcription factor.\",\n      \"evidence\": \"ChIP, in vitro binding, reporter assays, and transgenic mouse enhancer analysis\",\n      \"pmids\": [\"15592502\", \"15994290\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FLI1-MDM2-p53 axis operates in normal hematopoiesis versus only erythroleukemia not resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstration that FLI1, GATA2, and SCL co-occupy each other's enhancers in HSCs established a recursively wired triad circuit as the regulatory kernel of hematopoietic specification.\",\n      \"evidence\": \"ChIP across HSCs, fetal liver, and hemangioblast equivalents; enhancer-reporter and transgenic analysis\",\n      \"pmids\": [\"17962413\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Order of assembly and temporal hierarchy among the three factors not resolved\", \"Functional necessity of recursive wiring versus simple co-regulation not tested by enhancer mutation\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Placing FLI1 downstream of ETV2 and showing that FLI1 replaces ETV2 at its own promoter via positive autoregulation resolved how endothelial gene programs persist after ETV2 downregulation at midgestation.\",\n      \"evidence\": \"ChIP and loss/gain-of-function in mouse embryos and endothelial cell lines\",\n      \"pmids\": [\"24727028\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FLI1 is sufficient alone or requires ERG redundancy for endothelial maintenance in vivo\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Crystal structures of the FLI1 DNA-binding domain revealed a helix-swapped homodimer mediated by Phe362, separating dimerization from DNA-binding function and providing a structural framework for understanding FLI1 cooperativity on GGAA repeats.\",\n      \"evidence\": \"X-ray crystallography of free and DNA-bound FLI1 DBD, Phe362Ala mutagenesis, solution dimerization assays\",\n      \"pmids\": [\"26618620\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of dimerization for transcription in cells not established\", \"Full-length FLI1 structure unavailable\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrating that EWS-FLI1 directly interacts with splicing factors (DDX5, hnRNP K, RHA) via CLIP-seq and regulates alternative splicing established a non-canonical post-transcriptional function for the fusion beyond transcription.\",\n      \"evidence\": \"CLIP-seq, exon array, RNA-seq, co-IP, and pharmacological disruption with YK-4-279 in Ewing sarcoma cells\",\n      \"pmids\": [\"25737553\", \"25564528\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether wild-type FLI1 has any splicing regulatory activity unknown\", \"Specific RNA targets essential for transformation not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showing that p300/CBP/PCAF acetylate FLI1 at its DNA-binding domain to enhance DNA binding, while differentially modulating target gene-specific transactivation (enhancing some targets, reducing G-CSF promoter activity), revealed post-translational fine-tuning of FLI1 function.\",\n      \"evidence\": \"In vitro acetylation, EMSA, co-transfection with acetyltransferases, and site-directed mutagenesis of acetylation sites\",\n      \"pmids\": [\"22973553\", \"27431361\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Acetylation site specificity on full-length FLI1 in vivo not fully mapped\", \"Deacetylase(s) opposing this modification not identified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identifying the SPOP E3 ligase (via CK1-phosphorylated VTSSS degron) and OTUD7A/USP19 deubiquitinases as opposing regulators of EWS-FLI1 stability defined the ubiquitin-proteasome axis controlling fusion protein abundance in Ewing sarcoma.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, phosphodegron mutagenesis, knockdown with in vivo xenograft validation\",\n      \"pmids\": [\"34060252\", \"30700749\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SPOP-mediated degradation also governs wild-type FLI1 turnover in normal cells unknown\", \"Structural basis of OTUD7A recognition of EWS-FLI1 not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"An in vivo CRISPR screen identified FLI1 as a restraint on CD8+ T effector differentiation; its deletion increased chromatin accessibility at ETS:RUNX motifs and enhanced anti-tumor and anti-infection immunity without compromising memory, establishing FLI1 as a checkpoint of effector T cell fate.\",\n      \"evidence\": \"In vivo CRISPR screen, genetic deletion, ATAC-seq, ChIP-seq, infection and tumor challenge models in mice\",\n      \"pmids\": [\"33636129\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which FLI1 restricts Runx3 access is not structurally resolved\", \"Relevance in human T cells awaits confirmation\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"FLI1 was shown to limit NK cell memory precursor survival by inducing Bim downstream of STAT5, defining a parallel role to its T cell function in restricting lymphocyte effector/memory balance.\",\n      \"evidence\": \"scRNA-seq, ATAC-seq, STAT5 stimulation, genetic Fli1 manipulation, viral infection model\",\n      \"pmids\": [\"35288713\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct FLI1 binding to Bim regulatory elements not confirmed by ChIP\", \"Whether FLI1 and ETS1 are redundant in NK cells not resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"A CRISPR screen revealed that ETV6 competes with EWS-FLI1 at GGAA repeat enhancers; ETV6 loss hyper-activates EWS-FLI1 at these sites and drives SOX11-mediated mesenchymal differentiation, providing a direct competition mechanism that tunes EWS-FLI1 output.\",\n      \"evidence\": \"Domain-focused CRISPR screen, biochemical competition, ChIP-seq, dominant-interfering peptide, xenograft model\",\n      \"pmids\": [\"36658219\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this competition operates at all GGAA microsatellites or only select sites unclear\", \"Structural basis of ETV6–EWS-FLI1 competition not resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"FLI1 was identified as an orchestrator of IFN-γ-induced IDO1 transcription by recruiting CBP and STAT1 and opening chromatin at the IDO1 locus, thereby driving kynurenine-mediated immunosuppression — linking FLI1 to tumor immune evasion.\",\n      \"evidence\": \"ChIP, ATAC-seq, co-IP of FLI1–CBP–STAT1, pharmacological FLI1 inhibition, T cell functional assays\",\n      \"pmids\": [\"38816360\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FLI1-IDO1 axis operates across tumor types beyond those studied\", \"Identity of the pharmacological FLI1 inhibitor target specificity not fully characterized\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the full-length structure of FLI1 (only the DBD is crystallized), the physiological relevance of homodimerization for transcription, whether SPOP-CK1-mediated degradation regulates wild-type FLI1 in normal hematopoiesis, and whether FLI1's restraint on T/NK effector differentiation can be therapeutically exploited without disrupting its essential endothelial and megakaryocytic functions.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Full-length FLI1 structure absent\", \"Dimerization function in transcription unresolved\", \"Therapeutic window for FLI1 modulation in immunotherapy undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 7, 10, 14, 18, 19, 20]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 7, 8, 10, 11, 14, 15, 22, 29, 33]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 9, 18, 29, 33]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 7, 8, 10, 11, 14, 15, 22, 29, 33]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [13, 15, 25]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [14, 29, 31, 33]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [21, 27, 28]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [29, 25, 38]}\n    ],\n    \"complexes\": [\n      \"FLI1-GATA2-SCL triad\",\n      \"EWS-FLI1–RHA complex\",\n      \"FLI1–Sp1 complex\"\n    ],\n    \"partners\": [\n      \"EKLF\",\n      \"GATA2\",\n      \"SCL\",\n      \"ETV6\",\n      \"SRF\",\n      \"RHA\",\n      \"SPOP\",\n      \"OTUD7A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}